Arcutis Biotherapeutics, Inc. (ARQT) income statement
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.61+0.28 (+1.02%)
Close on Nov 18, 2026Market cap $3.47BP/E 125.5Yield –
Arcutis Biotherapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 91.1%
- Operating margin
- 7.4%
- Net margin
- 6.1%
- Return on equity, FY2025
- -9.3%
Financial strength
- Current ratio
- 2.92
- Debt to equity
- 0.49
- Debt to assets
- 22.3%
- Cash to current liabilities
- 21.3%
Valuation
- P/E ratio
- 125.5
- Price to sales
- 7.48
- Price to book
- 15.73
- Dividend yield
- –
See a number that looks wrong?